Literature DB >> 16492931

Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.

María J Pajares1, Isabel Zudaire, María D Lozano, Jackeline Agorreta, Gorka Bastarrika, Wenceslao Torre, Ana Remírez, Ruben Pio, Javier J Zulueta, Luis M Montuenga.   

Abstract

RATIONALE AND
PURPOSE: Low-dose spiral computerized axial tomography (spiral CT) is effective for the detection of small early lung cancers. Although published data seem promising, there has been a significant degree of discussion concerning the potential of overdiagnosis in the context of spiral CT-based screening. The objective of the current study was to analyze the phenotypic and genetic alterations in the small pulmonary malignancies resected after detection in the University of Navarra/International Early Lung Cancer Action Project spiral CT screening trial and to determine whether their malignant molecular features are similar to those of resected lung tumors diagnosed conventionally. EXPERIMENTAL
DESIGN: We analyzed 17 biomarkers of lung epithelial malignancy in a series of 11 tumors resected at our institution during the last 4 years (1,004 high-risk individuals screened), using immunohistochemistry and fluorescence in situ hybridization (FISH). A parallel series of 11 gender-, stage-, and histology-matched lung cancers diagnosed by other means except screening was used as control.
RESULTS: The molecular alterations and the frequency of phenotypic or genetic aberrations were very similar when screen-detected and nonscreen-detected lung cancers were compared. Furthermore, most of the alterations found in the screen-detected cancers from this study were concordant with what has been described previously for stage I-II lung cancer.
CONCLUSIONS: Small early-stage lung cancers resected after detection in a spiral CT-based screening trial reveal malignant molecular features similar to those found in conventionally diagnosed lung cancers, suggesting that the screen-detected cancers are not overdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492931     DOI: 10.1158/1055-9965.EPI-05-0320

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  1 in total

1.  Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Authors:  Roque Diaz; Paul A Nguewa; Ricardo Parrondo; Carlos Perez-Stable; Irene Manrique; Miriam Redrado; Raul Catena; Maria Collantes; Ivan Peñuelas; Juan Antonio Díaz-González; Alfonso Calvo
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.